肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析

R969.3%R978.7; 富马酸替诺福韦二吡呋酯(TDF)是慢性乙型肝炎的一线治疗用药,随着该药在全球范围内使用的增加,其所致肾损伤的不良事件也引起了业界重视.本文报道了1例61岁既往合并乙型肝炎病毒(HBV)感染的肝癌患者,于2022年3月中旬开始使用TDF,用药2个月后出现肾损伤,其间进行了2个疗程的多纳非尼联合信迪利单抗化疗,同时不规律服用双氯芬酸缓解疼痛.本文使用Naranjo's评估量表评估出与肾损伤可能相关的药物有TDF和信迪利单抗,可疑相关的药物为多纳非尼和双氯芬酸;结合患者的病情变化、药物致肾损伤的发生率、临床表现、发生时间、发生机制、合并用药及高危因素,最终判断...

Full description

Saved in:

Bibliographic Details
Published in	中国药房 Vol. 35; no. 7; pp. 866 - 871
Main Authors	曹磊, 汪丰, 刘继勇, 常莹莹
Format	Journal Article
Language	Chinese
Published	复旦大学附属肿瘤医院药剂科,上海 200032 01.04.2024 复旦大学上海医学院肿瘤学系,上海 200032
Subjects	文献分析药物不良反应 literature analysis adverse drug reaction hepatitis B virus renal injury liver cancer tenofovir disoproxil fumarate 肾损伤富马酸替诺福韦二吡呋酯乙型肝炎病毒肝癌
Online Access	Get full text
ISSN	1001-0408
DOI	10.6039/j.issn.1001-0408.2024.07.17

Cover

Abstract	R969.3%R978.7; 富马酸替诺福韦二吡呋酯(TDF)是慢性乙型肝炎的一线治疗用药,随着该药在全球范围内使用的增加,其所致肾损伤的不良事件也引起了业界重视.本文报道了1例61岁既往合并乙型肝炎病毒(HBV)感染的肝癌患者,于2022年3月中旬开始使用TDF,用药2个月后出现肾损伤,其间进行了2个疗程的多纳非尼联合信迪利单抗化疗,同时不规律服用双氯芬酸缓解疼痛.本文使用Naranjo's评估量表评估出与肾损伤可能相关的药物有TDF和信迪利单抗,可疑相关的药物为多纳非尼和双氯芬酸;结合患者的病情变化、药物致肾损伤的发生率、临床表现、发生时间、发生机制、合并用药及高危因素,最终判断为TDF导致的肾损伤.临床应动态监测肝癌合并HBV感染患者使用TDF后的血肌酐变化情况,必要时可调整抗病毒药物的剂量和选择其他对肾功能影响较小的抗病毒药物,以期为肿瘤患者提供个体化用药建议,降低TDF相关肾损伤发生率.
AbstractList	R969.3%R978.7; 富马酸替诺福韦二吡呋酯(TDF)是慢性乙型肝炎的一线治疗用药,随着该药在全球范围内使用的增加,其所致肾损伤的不良事件也引起了业界重视.本文报道了1例61岁既往合并乙型肝炎病毒(HBV)感染的肝癌患者,于2022年3月中旬开始使用TDF,用药2个月后出现肾损伤,其间进行了2个疗程的多纳非尼联合信迪利单抗化疗,同时不规律服用双氯芬酸缓解疼痛.本文使用Naranjo's评估量表评估出与肾损伤可能相关的药物有TDF和信迪利单抗,可疑相关的药物为多纳非尼和双氯芬酸;结合患者的病情变化、药物致肾损伤的发生率、临床表现、发生时间、发生机制、合并用药及高危因素,最终判断为TDF导致的肾损伤.临床应动态监测肝癌合并HBV感染患者使用TDF后的血肌酐变化情况,必要时可调整抗病毒药物的剂量和选择其他对肾功能影响较小的抗病毒药物,以期为肿瘤患者提供个体化用药建议,降低TDF相关肾损伤发生率.
Abstract_FL	Tenofovir disoproxil fumarate(TDF)is a first-line treatment for chronic hepatitis B.With increasing use worldwide,the adverse events of renal injury caused by this drug have also attracted industry attention.This article reports a 61-year-old patient with liver cancer complicated with hepatitis B virus(HBV)infection.The patient started using TDF in mid-March 2022 and developed kidney injury after 2 months of treatment,during which he received 2 courses of donafenib combined with sintilimab chemotherapy and irregular administration of diclofenac for pain relief.In this paper,Naranjo's assessment scale was used to evaluate the drugs that may be associated with renal injury,including TDF and sintilimab,and the drugs that are suspected to be associated with renal injury are donafenib and diclofenac.The renal injury caused by TDF can be judged according to the changes in the patient's condition,the incidence of drug-induced renal injury,clinical manifestations,occurrence time,occurrence mechanism,drug combination,and high-risk factors.The changes of serum creatinine in patients with liver cancer complicated with HBV infection after TDF should be dynamically monitored in the clinic,and the dose of antiviral drugs should be adjusted if necessary and other antiviral drugs with less impact on renal function can be selected,to provide individualized medication recommendations for tumor patients,reduce the incidence of TDF-related renal injury.
Author	常莹莹汪丰刘继勇曹磊
AuthorAffiliation	复旦大学附属肿瘤医院药剂科,上海 200032;复旦大学上海医学院肿瘤学系,上海 200032
AuthorAffiliation_xml	– name: 复旦大学附属肿瘤医院药剂科,上海 200032;复旦大学上海医学院肿瘤学系,上海 200032
Author_FL	CAO Lei WANG Feng LIU Jiyong CHANG Yingying
Author_FL_xml	– sequence: 1 fullname: CAO Lei – sequence: 2 fullname: WANG Feng – sequence: 3 fullname: LIU Jiyong – sequence: 4 fullname: CHANG Yingying
Author_xml	– sequence: 1 fullname: 曹磊 – sequence: 2 fullname: 汪丰 – sequence: 3 fullname: 刘继勇 – sequence: 4 fullname: 常莹莹
BookMark	eNo9UM1Kw0AY3EMF2-pTiMfE_bLb3exRi1qh4EW9lphsikVSMIjoSYq1hVasKIKIBlGKgtiLiBZtXya_b2FE8TTMwPwwOZRx6o5EaAawyjARczV1y3UdFTAGBVOsqxrWqIq5CjyDsv_yJMq5bg1jCoJBFhlx4ya66ga9dvDxVlrYCI-80DsPG_fxYdP_GkcXj8Ggmzw9J8338HocD4ZR_zTx-v4wtdwFZ52kOYhbr3FjFJ54_ucD-KNOGhRetqLuS9A-Dm97U2jCNrZdOf2HebS-tLhWLCnl1eWV4nxZcdNtXGEAUhBpAStIoenUpIwyMyXUBrapc84sW5gAQuoaMQtCEtAwt4gJlmSbmkbyaPY3d89wbMOpVmr13R0nbawcVPftnzMwx8DJNz2ueUA
ClassificationCodes	R969.3%R978.7
ContentType	Journal Article
Copyright	Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml	– notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID	2B. 4A8 92I 93N PSX TCJ
DOI	10.6039/j.issn.1001-0408.2024.07.17
DatabaseName	Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ)
DatabaseTitleList
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
DocumentTitle_FL	Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection:a case report and literature analysis
EndPage	871
ExternalDocumentID	zgyf202407017
GrantInformation_xml	– fundername: 吴阶平医学基金会课题 funderid: (No.320.6750.2023-10-6)
GroupedDBID	-05 2B. 4A8 5GY 5XA 5XF 92F 92I 93N ABJNI ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CW9 GROUPED_DOAJ PSX TCJ TGQ U1G U5O
ID	FETCH-LOGICAL-s1007-611e93ed165e9284c4646c65e4f16b8776df9c119e823c59e31207d3c1de6b223
ISSN	1001-0408
IngestDate	Thu May 29 04:00:04 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	文献分析药物不良反应 literature analysis adverse drug reaction hepatitis B virus renal injury liver cancer tenofovir disoproxil fumarate 肾损伤富马酸替诺福韦二吡呋酯乙型肝炎病毒肝癌
Language	Chinese
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-s1007-611e93ed165e9284c4646c65e4f16b8776df9c119e823c59e31207d3c1de6b223
PageCount	6
ParticipantIDs	wanfang_journals_zgyf202407017
PublicationCentury	2000
PublicationDate	2024-04-01
PublicationDateYYYYMMDD	2024-04-01
PublicationDate_xml	– month: 04 year: 2024 text: 2024-04-01 day: 01
PublicationDecade	2020
PublicationTitle	中国药房
PublicationTitle_FL	China Pharmacy
PublicationYear	2024
Publisher	复旦大学附属肿瘤医院药剂科,上海 200032 复旦大学上海医学院肿瘤学系,上海 200032
Publisher_xml	– name: 复旦大学附属肿瘤医院药剂科,上海 200032 – name: 复旦大学上海医学院肿瘤学系,上海 200032
SSID	ssj0041961 ssib051369179 ssib001103784 ssib017477153
Score	2.3490903
Snippet	R969.3%R978.7;...
SourceID	wanfang
SourceType	Aggregation Database
StartPage	866
Title	肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析
URI	https://d.wanfangdata.com.cn/periodical/zgyf202407017
Volume	35
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEF_aCuKL-Imf5UDTp17d7GazyWNyt0cRlD600rdyt7dbn06w7UP7JMXaQitWFEFED1GKgtgXES3a_i3CffW_cDK77W6l-AXHMpfM_GYmc7lMQpK1rKseJAkSfkfF2K7aRXP7SFHaMUxW_AiSV8nrIb6m88ZNPjrBrk96k339P3K7luZmayPhwqHnSv4nqlAGcTWnZP8hsvugUAA0xBeeEGF4_lWMSSCIcIgsk8AnUhJRIoFHpE2EMISWRPNRfYsEnAhGZMUQ8JQuljhEuYgA_B4JGNFloisIxYhCBFVBTEkUfJAATi0QRyOzMDxaGSkFmBXDAyqANoAqM0lRJCgROsVRKC58olnqiA7QsDKaCuIlohhFKkCx1CVUz40kaAUFKjBV4LNIqgKSvBt0L-lGBDC0jBZo46fRV0YLuBHU-_ub91yT6JFLhMrXaEqUSuG0ndWgdimMjNZE-ViiSTbIo-0Cmw40B4ifEvl1Fye_Xcf0FAwCM7Yau7CNk5JEB7hkSiQGn6ESavxPmzMJpjD8xqCSMS5hVk6uCaBKGn7jsW9C5JRSH4VCrwHWN3dP2vlFYorb5Jgt8qNccilM2pv93JAlOD-Q_dDDBlZuuxIHVqNgZF_BiGkYc_ltcv72l5vLF6bnY8MAowr1-60jju8nOynSVQ_M2M051eyoNMyPgSnLID3qconvyEuSKwYDBq6h7Flw1LqSmnftN8bhibxGXG1M55LH8RPW8XTWV1BJFz5p9S3cPmUNjSXXxs8PF8azU5Azw4Whwlh2ofz8aavaW3zZfb7WXl9pf_0M_blzv9lpPuksvundW2p93-k-fdfeXNt9_2F36UvnxU5vc6u78Wi3udHaApHX7ceru0ubveVPvcXtzsNm69tb2tpeBaDOs-Xu2sf2yoPOq_Uz1kQlGC-NFtNXoxRnzLamIqc0km5Up9yLJGSYIeOMh_CFxZTXhO_zeixDSmUkHDf0ZORSx_brbkjrEa_BlOCsNdC404jOWQW7CjOoUPqQbkQs9CPp1RkDHkjcY8CJz1uDadtNpX99M1MHInvhTwwXrWNZB7pkDczenYsuQyo_WxvEH8NPEUrBzQ
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%82%9D%E7%99%8C%E5%90%88%E5%B9%B6HBV%E6%84%9F%E6%9F%93%E6%82%A3%E8%80%85%E4%BD%BF%E7%94%A8%E5%AF%8C%E9%A9%AC%E9%85%B8%E6%9B%BF%E8%AF%BA%E7%A6%8F%E9%9F%A6%E4%BA%8C%E5%90%A1%E5%91%8B%E9%85%AF%E8%87%B4%E8%82%BE%E6%8D%9F%E4%BC%A41%E4%BE%8B%E5%B9%B6%E6%96%87%E7%8C%AE%E5%88%86%E6%9E%90&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%8D%AF%E6%88%BF&rft.au=%E6%9B%B9%E7%A3%8A&rft.au=%E6%B1%AA%E4%B8%B0&rft.au=%E5%88%98%E7%BB%A7%E5%8B%87&rft.au=%E5%B8%B8%E8%8E%B9%E8%8E%B9&rft.date=2024-04-01&rft.pub=%E5%A4%8D%E6%97%A6%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%8D%AF%E5%89%82%E7%A7%91%2C%E4%B8%8A%E6%B5%B7+200032&rft.issn=1001-0408&rft.volume=35&rft.issue=7&rft.spage=866&rft.epage=871&rft_id=info:doi/10.6039%2Fj.issn.1001-0408.2024.07.17&rft.externalDocID=zgyf202407017
thumbnail_s	http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgyf%2Fzgyf.jpg